HCC-话题@MedSci

#HCC#

115篇内容 | 6629人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259562, encodeId=e9db12595622b, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：Gd-EOB-DTPA增强MRI，实现HCC微血管浸润的无创评估！, objectType=article, longId=300420, objectId=9aee30042036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aee30042036, replyNumber=0, likeNumber=88, createdTime=2022-03-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aee30042036, moduleTitle=European Radiology：Gd-EOB-DTPA增强MRI，实现HCC微血管浸润的无创评估！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aee30042036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259561, encodeId=606e1259561f4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, objectType=article, longId=299277, objectId=87e42992e798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87e42992e798, replyNumber=0, likeNumber=91, createdTime=2022-02-22, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87e42992e798, moduleTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87e42992e798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259560, encodeId=d7371259560e9, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, objectType=article, longId=295066, objectId=890729506606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890729506606, replyNumber=0, likeNumber=98, createdTime=2022-02-04, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890729506606, moduleTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890729506606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259559, encodeId=45d4125955949, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效, objectType=article, longId=294717, objectId=7d23294e17f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d23294e17f3, replyNumber=0, likeNumber=78, createdTime=2022-01-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d23294e17f3, moduleTitle=Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d23294e17f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259557, encodeId=0c56125955ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值, objectType=article, longId=293038, objectId=658829303868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=658829303868, replyNumber=0, likeNumber=102, createdTime=2021-12-30, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=658829303868, moduleTitle=European Radiology：深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=658829303868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259556, encodeId=888f1259556ce, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, objectType=article, longId=292954, objectId=a2d3292954c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d3292954c0, replyNumber=0, likeNumber=69, createdTime=2021-12-29, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d3292954c0, moduleTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d3292954c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259558, encodeId=d9e812595586d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：如果你还不不知道HCC MTM亚型，那一定要看过来！, objectType=article, longId=292482, objectId=204129248231, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=204129248231, replyNumber=0, likeNumber=65, createdTime=2021-12-23, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=204129248231, moduleTitle=Radiology：如果你还不不知道HCC MTM亚型，那一定要看过来！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=204129248231)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259555, encodeId=e5ed12595551b, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, objectType=article, longId=221201, objectId=587522120103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=587522120103, replyNumber=0, likeNumber=71, createdTime=2021-11-30, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=587522120103, moduleTitle=Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=587522120103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259554, encodeId=4d151259554e4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=GRAMD1A在HCC发展和治疗中的作用, objectType=article, longId=221029, objectId=c4d0221029a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4d0221029a7, replyNumber=0, likeNumber=80, createdTime=2021-11-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4d0221029a7, moduleTitle=GRAMD1A在HCC发展和治疗中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4d0221029a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259553, encodeId=d64e1259553f2, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：在预测慢性乙型肝炎HCC的进展中，你知道这一评分系统吗？, objectType=article, longId=220827, objectId=3d7222082e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d7222082e46, replyNumber=0, likeNumber=98, createdTime=2021-11-24, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d7222082e46, moduleTitle=Radiology：在预测慢性乙型肝炎HCC的进展中，你知道这一评分系统吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d7222082e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259552, encodeId=94d712595522a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, objectType=article, longId=220495, objectId=dbd22204957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd22204957c, replyNumber=0, likeNumber=109, createdTime=2021-11-18, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd22204957c, moduleTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd22204957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259551, encodeId=418412595519a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=83, createdTime=2021-11-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259550, encodeId=6ade125955006, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, objectType=article, longId=219974, objectId=ad462199e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad462199e46a, replyNumber=0, likeNumber=73, createdTime=2021-11-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad462199e46a, moduleTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad462199e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259549, encodeId=c3cc125954919, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测, objectType=article, longId=219717, objectId=4c2b219e17ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c2b219e17ec, replyNumber=0, likeNumber=68, createdTime=2021-11-05, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c2b219e17ec, moduleTitle=European Radiology：Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c2b219e17ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259548, encodeId=bf58125954832, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, objectType=article, longId=219491, objectId=16ac219491e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ac219491e4, replyNumber=0, likeNumber=82, createdTime=2021-10-31, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ac219491e4, moduleTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ac219491e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259547, encodeId=c38b125954ed2, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, objectType=article, longId=219192, objectId=ab6d21919256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6d21919256, replyNumber=0, likeNumber=136, createdTime=2021-10-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6d21919256, moduleTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6d21919256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, objectType=article, longId=219191, objectId=02ce219191a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce219191a0, replyNumber=0, likeNumber=73, createdTime=2021-10-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce219191a0, moduleTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce219191a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259545, encodeId=965712595454d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, objectType=article, longId=219167, objectId=456221916eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456221916eb9, replyNumber=0, likeNumber=72, createdTime=2021-10-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456221916eb9, moduleTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456221916eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259544, encodeId=40681259544de, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, objectType=article, longId=218274, objectId=25462182e412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25462182e412, replyNumber=0, likeNumber=81, createdTime=2021-10-10, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25462182e412, moduleTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25462182e412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259543, encodeId=868b12595433e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, objectType=article, longId=217963, objectId=568c21e96338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=568c21e96338, replyNumber=0, likeNumber=96, createdTime=2021-10-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=568c21e96338, moduleTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=568c21e96338)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：Gd-EOB-DTPA增强MRI，实现HCC微血管浸润的无创评估！

2022-03-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS

2022-02-22

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后

2022-02-04

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效

2022-01-27

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值

2021-12-30

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性

2021-12-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：如果你还不不知道HCC MTM亚型，那一定要看过来！

2021-12-23

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：Atezolizumab (ATEZO) + bevacizumab (BEVA)一线治疗晚期HCC进展后，二线治疗选择对比

2021-11-30

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

GRAMD1A在HCC发展和治疗中的作用

2021-11-27

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：在预测慢性乙型肝炎HCC的进展中，你知道这一评分系统吗？

2021-11-24

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性

2021-11-18

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2021-11-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效

2021-11-10

仁医06 (审核中...)

前往app查看评论内容

#HCC#

European Radiology：Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测

2021-11-05

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效

2021-10-31

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效

2021-10-26

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性

2021-10-26

仁医06 (审核中...)

前往app查看评论内容

#HCC#

更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗

2021-10-25

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性

2021-10-10

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效

2021-10-02

科室
- - 订阅+
  - 更多科室
工具
服务